Table 1.
Participant characteristics summary table by neuropathologic grouping
| PSP (n = 2) | AD (n = 9) | AGD (n = 2a) | PART (n = 14) | PA (n = 7) | |
|---|---|---|---|---|---|
| Age at plasma, years | 80 (79,81) | 87 (84,90) | 89 (88,89) | 81 (78,84) | 79 (72,86) |
| Age at death, years | 82 (81,83) | 89 (86,92) | 90 (90,91) | 83 (81,86) | 80 (74,88) |
| Postmortem interval, hours | 4 (4,5) | 13 (9,18) | 20 (19,21) | 20 (18,22) | 14 (11,21) |
| Females | 0 (0%) | 4 (44%) | 1 (50%) | 8 (57%) | 2 (29%) |
| APOE ε4 positivity | 0 (0%) | 4 (44%) | 1 (50%) | 2 (14%) | 3 (43%) |
| Clinical Dementia Rating, 0–18 | 0.5 (0,1) | 4 (0.5,7) | 2 (1,3) | 0 (0,0) | 0 (0,0.5) |
| Mini-Mental State Examination, 0–30 | 29 (28,30) | 23 (23,27) | 28 (27,28) | 28 (28,29) | 28 (28,30) |
| Tau-PET parietal SUVr | n/a | 1.2 (1.1,1.3) | n/a | 1.0 (1.0,1.1) | 1.1 (1.1,1.1) |
| Fluid levels | |||||
| MSD plasma p-tau181, pg/mL | 1.6 (1.3,1.9) | 3.4 (2.5,4.3) | 1.7 (1.6,1.9) | 1.2 (0.9,1.5) | 1.3 (1.1,1.8) |
| MSD plasma p-tau217, pg/mL | 0.25 (0.21,0.29) | 0.69 (0.52,0.75) | 0.18 (0.17,0.20) | 0.15 (0.12,0.20) | 0.19 (0.17,0.29) |
| Creatinine, mg/dL | 1.0 (1.0,1.0) | 1.2 (0.9,1.3) | 1.4 (1.2,1.6) | 1.0 (1.0,1.4) | 1.1 (1.1,1.3) |
| ALT level, U/L | n/a | 22 (15,24) | 21 (21,21) | 21 (18,27) | 19 (18,47) |
| AST level, U/L | 24 (21,27) | 23 (19,29) | 18 (15,20) | 26 (23,31) | 28 (22,49) |
| Global scales | |||||
| Braak stage, 0-VI | III (III, III) | IV (IV, V) | II (II, II) | II (II, III) | II (II, II) |
| 0 | I | II | III | IV | V | VI, counts | 0|0|0|2|0|0|0 | 0|0|0|0|5|3|1 | 0|0|2|0|0|0|0 | 1|3|4|5|1|0|0 | 0|2|4|1|0|0|0 |
| Thal phase, 0–5 | 3 (3,3) | 5 (4,5) | 0.5 (0,1) | 1 (1,2) | 3 (3,4) |
| 0 | 1 | 2 | 3 | 4 | 5, counts | 0|0|0|2|0|0 | 0|0|0|2|2|5 | 1|1|0|0|0|0 | 3|6|5|0|0|0 | 0|0|0|4|3|0 |
| Diffuse plaques, Moderate-Frequent | 2 (100%) | 9 (100%) | 1 (50%) | 3 (21%) | 7 (100%) |
| Neuritic plaques, Moderate-Frequent | 2 (100%) | 9 (100%) | 0 (0%) | 1 (7%) | 4 (57%) |
| LATE-NC stage, 0–3 | 0 (0,0) | 1 (0,2) | 1 (1,2) | 0 (0,0) | 0 (0,0) |
| Kalaria CVD score, 0–10 | 3 (3,3) | 4 (3,5) | 6 (5,6) | 2 (2,4) | 3 (2,5) |
| Regional measures | |||||
| Parietal pT181, % | 0.27 (0.27,0.27) | 0.64 (0.54,0.93) | 0.27 (0.22,0.32) | 0.17 (0.12,0.22) | 0.11 (0.080,0.23) |
| Parietal pT217, % | 0.46 (0.38,0.55) | 0.63 (0.38,4.9) | 0.22 (0.20,0.25) | 0.080 (0.060,0.090) | 0.11 (0.10,0.12) |
| Parietal amyloid-β, % | 2.7 (2.5,3.0) | 2.7 (2.0,4.6) | 0.24 (0.16,0.32) | 0.16 (0.10,0.46) | 1.1 (0.43,1.5) |
| Hippocampal pT181, % | 0.58 (0.41,0.74) | 2.5 (1.9,3.9) | 0.84 (0.51,1.2) | 0.28 (0.18,0.34) | 0.34 (0.16,0.38) |
| Hippocampal pT217, % | 4.8 (3.0,6.6) | 21 (10,28) | 6.6 (3.5,9.7) | 2.3 (0.34,3.7) | 0.95 (0.67,2.7) |
| Hippocampal amyloid-β, % | 0.36 (0.25,0.47) | 0.64 (0.16,1.8) | 0.050 (0.040,0.050) | 0.050 (0.040,0.12) | 0.11 (0.060,0.34) |
| LC neurons/mm2 | 25 (18,33) | 30 (22,33) | 22 (22,22) | 44 (38,52) | 45 (39,52) |
| nbM neurons/mm2 | 14 (11,17) | 19 (14,19) | 30 (26,35) | 22 (17,27) | 20 (15,29) |
Data presented are median and interquartile range (25th,75th). aAGD case with high creatinine was not included. Acronyms: AD Alzheimer’s disease, AGD Argyrophilic grains disease, ALT Alanine transaminase, AST Aspartate aminotransferase, CVD Cerebrovascular disease, CAA Cerebral amyloid angiopathy, LATE-NC Limbic-predominant age-related TDP-43 encephalopathy neuropathologic change, LC Locus coeruleus, MSD Meso scale discovery. p-tau phosphorylated tau in plasma, n/a not available, nbM nucleus basalis of Meynert, PA Pathological aging, PART Primary age-related tauopathy, PSP Progressive supranuclear palsy, pT phosphorylated threonine for immunohistochemical measures of tau